By Karen Roman
Oncology-focused biotech company SkylineDx said results from its MERLIN_001 trial, the largest evaluation of a genomic test in cutaneous melanoma, were published in the October 2025 issue of JAMA Surgery.
The study shows the test classified T1-T3 melanomas with unique risk levels for sentinel node metastasis, the company stated.
The trial included 1,761 patients across diverse U.S. cancer centers like Mayo Clinic, University of Louisville, and University of Michigan, among others, it said.
“This study represents a major step forward in evaluating personalized melanoma care,” declared Vernon Sondak, MD, MERLIN_001 Principal Investigator. “Studying the Merlin CP-GEP Test’s ability to distinguish patients’ risk of sentinel node metastasis with a rigor and precision no other test or nomogram can match.”
READ MORE
Final Agenda: 5th Palm Beach CorpGov Forum Nov 5-6 with NYSE and Goldman Sachs
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
